Proposal relating to the listing of docusate sodium with sennosides tablet 50 mg with total sennosides 8 mg and prednisolone sodium phosphate oral liquid 5 mg per ml
PHARMAC is seeking feedback on a proposal relating to provisional agreements for supply of the oral tablet docusate sodium with sennosides (“Laxsol”) and for prednisolone sodium phosphate oral liquid (“Redipred”). Closes: Friday, 17 October 2014.
September 2014 tender notification
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2013/14 Invitation to Tender, dated 07 November 2013.
First funded treatment for motor neurone disease
The first funded pharmaceutical treatment for Amyotrophic Lateral Sclerosis (ALS), the most common form of motor neurone disease, will become available from 1 October 2013.
Addition of Coloplast range of wound care products to Universal Specialities Limited trading as USL Medical (USL) listing agreement
PHARMAC advises that as of 1 October 2014, a range of Coloplast wound care products already in use in the DHBs, will be added to the USL Listing Agreement and listed in Section H, Part III, (‘Optional Pharmaceuticals’) of the Pharmaceutical Schedule.
Jadelle (levonorgestrel 2 x 75 mg rods) funding proposal approved
PHARMAC is pleased to announce the approval for the listing and supply of levonorgestrel 2 x 75 mg rods (Jadelle).
Proposal to list a range of interventional cardiology products supplied by Bio-Excel (Australia) Pty Ltd
PHARMAC is seeking feedback on a proposal to list a range of interventional cardiology products supplied by Bio-Excel (Australia) Pty Ltd (“Bio-Excel”) in Part III of Section H of the Pharmaceutical Schedule from 1 November 2014. Closes: Monday, 13 October 2014.
Listing of various contrast media
PHARMAC is pleased to announce decisions relating to various contrast media that will take effect from 1 October 2014 through an agreement with Regional Health Limited.
Proposal to list ceftaroline fosamil in Section H of the Pharmaceutical Schedule
PHARMAC is seeking feedback on a proposal to list ceftaroline fosamil in Part II of Section H of the Pharmaceutical Schedule. Closes: Friday, 19 September 2014.
Clarification: Be aware of different potency with newly listed Qvar (beclomethasone) inhalers
The smaller particles delivered by the newly-funded Qvar inhalers mean patients changing to this presentation will usually require lower doses.
RFT - Supply of infliximab to DHB hospitals
PHARMAC requests tenders for the supply of infliximab to DHB hospitals in New Zealand. Closes: 5 pm Tuesday, 30 September 2014.
Decisions to amend or remove restrictions on various funded pharmaceuticals
PHARMAC is pleased to announce decisions to remove or amend the funding restrictions for a number of pharmaceuticals.
Proposal for sole subsidised supply of a contraceptive implant
PHARMAC is seeking feedback on a proposal to fund a contraceptive implant in Section B and in Part II of Section H of the Pharmaceutical Schedule from 1 October 2014.
Agreement with Jackson Allison Medical & Surgical Limited for the supply of wound care products
PHARMAC is pleased to announce the approval of an agreement with Jackson Allison Medical & Surgical Limited (“Jackson Allison”) for the supply of wound care products
Genetic markers being used to target new oral hepatitis C drug
Genetic markers will be used to target a new funded oral treatment for hepatitis C patients from 1 September.
Amendment to the terms of listing of disposable laparoscopic supplies on the Pharmaceutical Schedule
PHARMAC notification to amend agreement with Applied Medical New Zealand Limited for disposable laparoscopic devices.
Two new treatments funded for blood disorders and cancers
Up to 400 patients a year are likely to live longer as a result of PHARMAC funding two new medicines.
PHARMAC tender for generic medicines contributes $38 million savings
New Zealanders’ use of generic medicines is likely to grow further following the just-completed 2013/14 PHARMAC tender.
Feedback on draft RFP for medicines for rare disorders
PHARMAC is pleased to announce the outcome of the consultation on the draft request for proposals for supply of medicines for rare disorders.
Savings for DHBs in medical equipment agreement
DHBs will save another $650,000 a year from lower priced wound care and surgery equipment through a new national PHARMAC agreement with a major medical device supplier.
RFP - Supply of medicines for rare disorders
PHARMAC is interested in considering proposals from suppliers of medicines for rare disorders for the funding and listing of their products in the Pharmaceutical Schedule. Closes: 5 pm, 25 September 2014.
Newsletters
Device Advice: Your update on PHARMAC’s Hospital Medical Devices programme.
Media queries
021 863 342
Media phone is monitored 9am–5pm weekdays
